Why the study?
Do angiotensin-converting enzyme inhibitors improve efficacy and tolerability compared to nonpharmacological therapy and other antihypertensive agents in patients with mild arterial hypertension?
Do angiotensin-converting enzyme inhibitors improve efficacy and tolerability compared to nonpharmacological therapy and other antihypertensive agents in patients with mild arterial hypertension?
ACE inhibitors are a suitable first-step pharmacological therapy for mild hypertension due to their efficacy, tolerability, and favorable metabolic, renal, and cardiac effects.
Answers are grounded in this paper and cite their sources.
Supports ACE inhibitors as initial therapy in mild hypertension; leaves open prospective randomized confirmation.
Angiotensin-converting enzyme inhibitors are nowadays widely employed for the treatment of arterial hypertension. They exhibit comparable levels of efficacy and better tolerability when compared with the other antihypertensive agents. In mild arterial hypertension they have been shown to be more efficacious than nonpharmacological therapy that is recommended as the first-step therapeutic approach for most cases of this type of hypertension. Potential advantages for the control of associated metabolic risk factors and specific renal and cardiac effects make these drugs suitable for the first step pharmacological therapy on mild hypertension.
No takes yet. Share an insight, caveat, or question.
Rodicio et al. (1993) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: